Revenue Growth Driven by Products Launched in the Last Twelve Months Company Revises Guidance for 2012 SCHAUMBURG, Ill., Aug. 9, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced financial results for the quarter ended June 30, 2012. Second Quarter 2012 Highlights
- Revenue increased 32% to $42.7 million driven by products launched in the last twelve months;
- Reported gross profit increased to $6.5 million, or 15.2% inclusive of $1.2 million of margin from the sale of heparin inventory previously written off through excess inventory reserves;
- Launched Atracurium Besylate and Irinotecan; and
- Key manufacturing partner's facility found acceptable by FDA, clearing pathway for multiple product approvals and four to six new product launches during the second half of 2012.